Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of “Hold” from Brokerages

Precigen, Inc. (NASDAQ:PGEN) has been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $12.50.

Several research firms have recently weighed in on PGEN. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. HC Wainwright boosted their target price on shares of Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Finally, Citigroup restated an “outperform” rating on shares of Precigen in a report on Thursday, May 14th.

Insider Activity

In related news, CFO Harry Jr. Thomasian sold 41,884 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $182,614.24. Following the completion of the sale, the chief financial officer directly owned 554,535 shares of the company’s stock, valued at approximately $2,417,772.60. This represents a 7.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Randal J. Kirk sold 4,772,781 shares of the firm’s stock in a transaction dated Monday, March 30th. The stock was sold at an average price of $3.30, for a total value of $15,750,177.30. Following the sale, the director owned 302,213 shares of the company’s stock, valued at $997,302.90. The trade was a 94.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,005,749 shares of company stock valued at $16,765,918 in the last ninety days. Corporate insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Several institutional investors have recently made changes to their positions in PGEN. Xponance LLC grew its position in Precigen by 21.3% during the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Precigen by 6.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after buying an additional 2,993 shares during the period. Composition Wealth LLC boosted its stake in shares of Precigen by 16.5% during the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after buying an additional 3,000 shares during the period. Intech Investment Management LLC grew its holdings in shares of Precigen by 5.2% during the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 3,137 shares in the last quarter. Finally, Cetera Investment Advisers grew its holdings in shares of Precigen by 0.9% during the 1st quarter. Cetera Investment Advisers now owns 374,514 shares of the biotechnology company’s stock valued at $1,449,000 after acquiring an additional 3,250 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Stock Performance

Shares of PGEN opened at $4.45 on Monday. The business’s 50-day moving average price is $4.12 and its 200 day moving average price is $4.07. The stock has a market capitalization of $1.59 billion, a P/E ratio of -3.77 and a beta of 1.06. Precigen has a 1-year low of $1.38 and a 1-year high of $5.47. The company has a current ratio of 4.82, a quick ratio of 4.12 and a debt-to-equity ratio of 4.62.

Precigen (NASDAQ:PGEN) last posted its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The firm had revenue of $23.25 million for the quarter, compared to the consensus estimate of $20.81 million. Analysts expect that Precigen will post -0.02 earnings per share for the current year.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.